Vadimezan (Standard)

• Description:

  Vadimezan (Standard) (DMXAA (Standard) ) is the analytical standard of Vadimezan (HY-10964) . This product is intended for research and analytical applications. Vadimezan (DMXAA; ASA-404), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.

• Product Name Alternative:

  DMXAA (Standard) ; ASA-404 (Standard)

• UNSPSC:

  12352005

• Target:

  IFNAR; Influenza Virus; Reference Standards; STING

• Related Pathways:

  Anti-infection; Immunology/Inflammation; Others

• Field of Research:

  Cancer; Infection

• Smiles:

  O=C (O) CC1=CC=CC (C2=O) =C1OC3=C2C=CC (C) =C3C

• Molecular Formula:

  C17H14O4

• Molecular Weight:

  282.29

• References & Citations:

  [1]Downey CM, et al. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization. PLoS One. 2014 Jun 18;9 (6) :e99988.|[2]Shirey KA, et al. The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. J Leukoc Biol. 2011 Mar;89 (3) :351-7.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference Standards

• Clinical Information:

  No Development Reported

• CAS Number:

  117570-53-3